


### **MEDICINAL PRODUCTS 2022**

### **ImmuCell**

# IMMUCELL CORP DE Rank 12 of 51





#### **MEDICINAL PRODUCTS 2022**

#### **ImmuCell**

# IMMUCELL CORP DE Rank 12 of 51

The relative strengths and weaknesses of IMMUCELL CORP DE are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of IMMUCELL CORP DE compared to the market average is the variable Property, Plant and Equipment, Net, increasing the Economic Capital Ratio by 42% points. The greatest weakness of IMMUCELL CORP DE is the variable Liabilities, Non-Current, reducing the Economic Capital Ratio by 22% points.

The company's Economic Capital Ratio, given in the ranking table, is 98%, being 112% points above the market average of -14%.

Input Variable	Value in 1000 USD
Assets, Current	16,265
Assets, Non-Current	1,135
General and Administrative Expense	14,817
Goodwill	172
Liabilities, Current	2,534
Liabilities, Non-Current	9,354
Other Assets	0
Other Compr. Net Income	0
Other Expenses	9.2
Other Liabilities	0
Other Net Income	-327
Other Revenues	19,243
Property, Plant and Equipment, Net	26,894
Research and Development	4,169

Output Variable	Value in 1000 USD
Liabilities	11,889
Assets	44,466
Expenses	18,995
Revenues	19,243
Stockholders Equity	32,577
Net Income	-78
Comprehensive Net Income	-78
Economic Capital Ratio	98%

